D-0983-2020 Class II Terminated
FDA drug recall D-0983-2020 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jan 15, 2020 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Dec 7, 2023).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 11, 2020
- Initiation Date
- Jan 15, 2020
- Termination Date
- Dec 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Testosterone Cypionate Injection,TESTOSTERONE CYP IN GRAPESEED OIL [10ML] 200 MG/ML INJECTABLE, For IM Use, 10 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0530-1
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic
Code information
Lot #: 03252019+51850, Exp 7/6/2020; 04252019+52098, Exp 6/29/2020; 04292019+52108, Exp 6/29/2020; 05012019+52132, Exp 10/22/2020; 05202019+52268, Exp 11/10/2020; 05222019+52290, Exp 11/10/2020; 05302019+52334, Exp 11/20/2020; 07082019+52594, Exp 12/29/2020; 07102019+52619, Exp 12/29/2020; 07292019+52762, Exp 8/12/2020; 07312019+52778, Exp 8/12/2020; 09102019+52898, Exp 1/16/2021; 09112019+52905, Exp 1/18/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0983-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026